DNA/Amphiphilic Block Copolymer Nanospheres Reduce Asthmatic Response in a Mouse Model of Allergic Asthma

Beilvert, F.; Tissot, A. N.; Langelot, Marie; Mével, Mathieu; Chatin, Benoît; Lair, David; Magnan, A.; Pitard, Bruno

doi:10.1089/hum.2012.024

Cited by 20 publications

(14 citation statements)

References 23 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Because we previously ascertained in our mouse model using female Balb/c mice that Penh was similar to resistance or other measures determined by FLEXIVENT, intubation (not shown) and whole body plethysmography were determined to be sufficient to explore respiratory function.…”

Section: Journal Of Agricultural and Food Chemistrymentioning

confidence: 95%

Consecutive Food and Respiratory Allergies Amplify Systemic and Gut but Not Lung Outcomes in Mice

Bouchaud

Gourbeyre

Bihouée

et al. 2015

J. Agric. Food Chem.

Self Cite

View full text Add to dashboard Cite

Epidemiological data suggest a link between food allergies and the subsequent development of asthma. Although this progression may result from the additional effects of exposure to multiple allergens, whether both allergies amplify each other's effects remains unknown. This study investigated whether oral exposure to food allergens influences the outcomes of subsequent respiratory exposure to an asthma-inducing allergen. Mice were sensitized and orally challenged with wheat (FA) and then exposed to house dust mite (HDM) extract (RA). Immunoglobulin (Ig), histamine, and cytokine levels were assayed by ELISA. Intestinal and lung physiology was assessed. Ig levels, histamine release, and cytokine secretion were higher after exposure to both allergens than after separate exposure to each. Intestinal permeability was higher, although airway hyper-responsiveness and lung inflammation remained unchanged. Exposure to food and respiratory allergens amplifies systemic and gut allergy-related immune responses without any additional effect on lung function and inflammation.

show abstract

Section: Journal Of Agricultural and Food Chemistrymentioning

confidence: 95%

Consecutive Food and Respiratory Allergies Amplify Systemic and Gut but Not Lung Outcomes in Mice

Bouchaud

Gourbeyre

Bihouée

et al. 2015

J. Agric. Food Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, full protection against anaphylaxis and survival of the mice was only achieved by OVA plus LPS‐entrapped NPs . Poloxamine (copolymers of ethylene oxide and propylene oxide) nanospheres loaded with Der f 1 plasmid were tested regarding therapeutic effect on asthmatic mice, and a reduction of airway hyperreactivity together with a decrease in inflammatory cytokines in the BAL could be observed …”

Section: Nonbiodegradable Nanostructuresmentioning

confidence: 99%

Recent advances in the use of nanoparticles for allergen‐specific immunotherapy

Pohlit

Bellinghausen

Frey

et al. 2017

Allergy

View full text Add to dashboard Cite

The number of patients suffering from allergic asthma and rhinoconjunctivitis has increased dramatically within the last decades. Allergen‐specific immunotherapy (AIT) is the only available cause‐oriented therapy so far. AIT reduces symptoms, but has also a disease‐modifying effect. Disadvantages are a long‐lasting procedure, and in a few cases potential systemic adverse reactions. Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages compared to the conventional AIT with noncapsulated allergen extracts: The protein/DNA molecule can be protected from degradation, higher local concentrations and targeted delivery to the site of action appear possible, and most importantly, recognition of encapsulated allergen by the immune system, especially by IgE antibodies, is prevented. AIT with nanoparticles (NPs) may offer a safer and potentially more efficient way of treatment for allergic diseases. In this review, we summarize the use of biodegradable NPs consisting of synthetic or natural polymers, liposomes, and virus‐like particles as well as nonbiodegradable NPs like dendrimers, and carbon‐ or metal‐based NPs for AIT. More or less successful applications of these NPs in prophylactic as well as therapeutic vaccination approaches in rodents or other animals as well as first human clinical trials are discussed in detail.

show abstract

“…84 Nanoparticles based on tetrafunctional block copolymer 704 have also been proposed for gene delivery. 85 When these nanoparticles, which contain a pDNA encoding for the allergen Dermatophagoides farinae 1 (Der f 1), were intramuscularly administered to healthy mice they induced strong humoral and cellular responses with a Th-1 profile. However, in asthmatic mice, the same nanoparticles led to a reduction of symptoms and a significant decrease in the level of inflammatory cytokines in bronchoalveolar lavage fluids.…”

Section: Parenteral Administrationmentioning

confidence: 99%

Adjuvants for allergy immunotherapeutics

Gamazo

D'Amelio

Gastaminza

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response. This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least 2 major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies. This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.

show abstract

DNA/Amphiphilic Block Copolymer Nanospheres Reduce Asthmatic Response in a Mouse Model of Allergic Asthma

Cited by 20 publications

References 23 publications

Consecutive Food and Respiratory Allergies Amplify Systemic and Gut but Not Lung Outcomes in Mice

Consecutive Food and Respiratory Allergies Amplify Systemic and Gut but Not Lung Outcomes in Mice

Recent advances in the use of nanoparticles for allergen‐specific immunotherapy

Adjuvants for allergy immunotherapeutics

Contact Info

Product

Resources

About